Department of Bioengineering, National Institute of Technology Agartala, West Tripura 799046, India.
Department of Chemistry, National Institute of Technology Agartala, West Tripura 799046, India.
Int J Pharm. 2023 Jun 10;640:123018. doi: 10.1016/j.ijpharm.2023.123018. Epub 2023 May 4.
Tuberculosis is a major health issue globally and a leading cause of death due to the infective microorganism Mycobacterium tuberculosis. Treatment of drug resistance tuberculosis requires longer treatment with multiple daily doses of drugs. Unfortunately, these drugs are often associated with poor patient compliance. In this situation, a need has been felt for the less toxic, shorter, and more effective treatment of the infected tuberculosis patients. Current research to develop novel anti-tubercular drugs shows hope for better management of the disease. Research on drug targeting and precise delivery of the old anti-tubercular drugs with the help of nanotechnology is promising for effective treatment. This review has discussed the status currently available treatments for tuberculosis patients infected with Mycobacterium alone or in comorbid conditions like diabetes, HIV and cancer. This review also highlighted the challenges in the current treatment and research on the novel anti-tubercular drugs to prevent multi-drug-resistant tuberculosis. It presents the research highlights on the targeted delivery of anti-tubercular drugs using different nanocarriers for preventing multi-drug resistant tuberculosis. Report has shown the importance and development of the research on nanocarriers mediated anti-tubercular delivery of the drugs to overcome the current challenges in tuberculosis treatment.
结核病是全球的一个主要健康问题，也是由感染性微生物结核分枝杆菌引起的主要死亡原因。治疗耐药结核病需要更长时间的治疗，每天需要多次服用多种药物。不幸的是，这些药物通常与较差的患者依从性有关。在这种情况下，人们迫切需要对感染结核病的患者进行毒性更小、疗程更短、更有效的治疗。目前开发新型抗结核药物的研究为更好地治疗该疾病带来了希望。借助纳米技术对靶向药物和旧的抗结核药物进行精确传递的研究为有效治疗提供了希望。这篇综述讨论了目前针对单独感染结核分枝杆菌或合并糖尿病、HIV 和癌症等合并症的结核病患者的治疗方法。还强调了目前治疗和研究新型抗结核药物预防耐多药结核病方面的挑战。它介绍了使用不同纳米载体靶向传递抗结核药物以预防耐多药结核病的研究亮点。报告表明，研究纳米载体介导的药物抗结核传递对于克服结核病治疗中的当前挑战具有重要意义和发展。
